Pathstone Family Office LLC Raises Holdings in Eli Lilly and Company (LLY)
Pathstone Family Office LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 100.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 58 shares of the company’s stock after buying an additional 29 shares during the quarter. Eli Lilly and accounts for approximately 1.1% of Pathstone Family Office LLC’s portfolio, making the stock its 8th largest holding. Pathstone Family Office LLC’s holdings in Eli Lilly and were worth $4,774,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Group Inc. grew its position in Eli Lilly and by 3.3% during the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after buying an additional 2,181,701 shares during the period. BlackRock Inc. grew its position in Eli Lilly and by 2.1% during the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock worth $5,232,942,000 after buying an additional 1,323,259 shares during the period. State Street Corp grew its position in Eli Lilly and by 1.6% during the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock worth $3,563,230,000 after buying an additional 651,424 shares during the period. Geode Capital Management LLC grew its position in Eli Lilly and by 8.4% during the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after buying an additional 708,597 shares during the period. Finally, Janus Capital Management LLC grew its position in Eli Lilly and by 2.8% during the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock worth $733,731,000 after buying an additional 237,619 shares during the period. Institutional investors own 75.68% of the company’s stock.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last ninety days, insiders have sold 770,000 shares of company stock worth $64,669,850. 0.20% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Pathstone Family Office LLC Raises Holdings in Eli Lilly and Company (LLY)” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/12/pathstone-family-office-llc-raises-holdings-in-eli-lilly-and-company-lly.html.
Several analysts have issued reports on LLY shares. UBS AG downgraded shares of Eli Lilly and to a “hold” rating and set a $85.00 price target on the stock. in a report on Wednesday, July 26th. BMO Capital Markets reaffirmed a “sell” rating and issued a $71.00 price target on shares of Eli Lilly and in a report on Thursday, September 28th. Morgan Stanley set a $86.00 price target on shares of Eli Lilly and and gave the company a “hold” rating in a report on Friday, October 6th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a report on Friday, October 13th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a report on Friday, August 4th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. Eli Lilly and has an average rating of “Hold” and a consensus price target of $89.76.
Eli Lilly and Company (NYSE LLY) opened at $83.29 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The firm has a market cap of $91,710.20, a P/E ratio of 20.36, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34. Eli Lilly and Company has a one year low of $64.18 and a one year high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and’s revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.88 earnings per share. equities analysts expect that Eli Lilly and Company will post 4.22 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.50%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is currently 98.58%.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.